DISCUSSION
Sorafenib single agent continues to be the only U.S. Food and Drug Administration-approved systemic therapy for hepatocellular carcinoma (HCC) in 2017 since its approval almost 10 years ago. This study showed that the combination of sorafenib and capecitabine in patients with advanced HCC is an active and safe palliative regimen. The disease response rate observed in this study was higher than the outcomes reported by other studies using sorafenib as single agent [1, 2] . The small sample size did not allow determining if this observation translated into a better survival outcome as compared with single-agent sorafenib. Such a determination will require a randomized phase II trial.
Oral capecitabine has been used as single agent in hepatobiliary cancers, with a median overall survival of 10 months in patients with HCC and well tolerated in cirrhotic patients [3] . Other investigators have explored different combinations with capecitabine, including platinum-based agents and other biological agents targeting vascular endothelial growth factor (VEGF) [4] [5] [6] . All of these studies have shown comparable results with similar treatment toxicity profile. 
Clinical Trial Results
Similar to data reported in previous studies [1, 2, 7] , 46% of our patients had been pretreated with locoregional treatments. Transarterial chemoembolization was the most commonly used locoregional modality prior to the beginning of systemic therapy in our population; this observation is consistent with data previously reported by other investigators and the current standard of care guidelines for the management of intermediate-stage, unresectable, and multifocal HCC [2, 8, 9] .
There were two exceptional responders in this study: one patient had a complete response that lasted 14 months, and another patient had a very good partial response for a duration of 11 months; this patient died of complications from cirrhosis while his cancer was still under good control.
The observed rate of serious adverse events was similar to the results from other studies, supporting the published data regarding the safety of sorafenib in Child-Pugh B patients [7, [10] [11] [12] . Moreover, the addition of capecitabine, with dose adjustment as tolerated, did not seem to increase the rate of serious adverse events; there were no treatment-related deaths, and dosage adjustments were performed as necessary (Table 1) . 
TRIAL INFORMATION
Number of Patients, Male 65 Number of Patients, Female 3 Stage Not collected Age Median (range): 65 (58-80) Number of Prior Systemic Therapies Median (range): 0 (0-2) Performance Status: ECOG 0-7 1-5 2-1 3-Unknown-
Other
Complete baseline demographic and disease characteristics are presented in Table 2 . This study showed that the combination of sorafenib and capecitabine in patients with advanced hepatocellular carcinoma (HCC) is an active and safe palliative regimen. The disease response rate observed in this study was higher than the outcomes reported by other studies using sorafenib as single agent [1, 2] . The small sample size did not allow determining if this observation translated into a better survival outcome as compared with single-agent sorafenib. Such a determination will require a randomized phase II trial.
PRIMARY ASSESSMENT METHOD FOR PHASE II STUDY
Oral capecitabine has been used as single agent in hepatobiliary cancers, with a median overall survival of 10 months in patients with HCC and well tolerated in cirrhotic patients [3] . Other investigators have explored different combinations with capecitabine, including platinum-based agents and other biological agents targeting vascular endothelial growth factor [4] [5] [6] . All of these studies have shown comparable results with similar treatment toxicity profile.
Similar to data reported in previous studies [1, 2, 7] , 46% of our patients had been pretreated with locoregional treatments. Trans-arterial chemoembolization (TACE) was the most commonly used locoregional modality prior to the beginning of systemic therapy in our population; this observation is consistent with data previously reported by other investigators and the current standard of care guidelines for the management of intermediate-stage, unresectable, and multifocal HCC [2, 8, 9] .
One patient had a prolonged complete response (CR) observed during the first 14 months since the beginning of the study regimen. The CR lasted for 11 months before disease progression (Figs. 2A, 2B, 3 ). Another patient on this trial experienced a good partial response and improvement in tumor markers; however, this patient experienced worsening cirrhosis and died of complications of liver cirrhosis (Figs. 4A, 4B, 5) .
Of note, this study population had a higher proportion of Child-Pugh class B; (B-7) patients compared with other studies (46% vs. 5% and 28% in the SHARP trial and GIDEON study, respectively), and similar prevalence of viral hepatitis infection and alcohol use in the HCC populations from North America analyzed in those same studies. The observed rate of serious adverse events was similar to the results from other studies, supporting the published data regarding the safety of sorafenib in Child-Pugh B patients [7, [10] [11] [12] . Moreover, the addition of capecitabine, with dose adjustment as tolerated, did not seem to increase the rate of serious adverse events.
Our study represents the first trial combining sorafenib and capecitabine in the management of advanced, unresectable HCC with findings supporting the activity and safety of this regimen. The small sample size does not allow comparison with single-agent sorafenib or capecitabine and/or in combination with other systemic treatments. Additional phase III data and studies of a larger scale will be necessary to determine if the combination of these two active agents might result in better survival outcomes when compared with the current standard of care. 
